Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.67 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.67 |
| ▸ | PPARG | P37231 | 1/20 | 0.66 |
| ▸ | PPARA | Q07869 | 1/20 | 0.66 |
| ▸ | ACE | P12821 | 1/20 | 0.61 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.58 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.57 |
| ▸ | FPR2 | P25090 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | LDHA | P00338 | 1/20 | 0.55 |
| ▸ | CTSS | P25774 | 6/20 | 0.55 |
| ▸ | CTSK | P43235 | 5/20 | 0.55 |
| ▸ | CTSL | P07711 | 1/20 | 0.54 |
| ▸ | CTSB | P07858 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL335310 | 1.00 | ITGB3 (0.67) | ITGB3ITGA2BPPARGPPARAACE | |
| SCHEMBL1308867 | 1.00 | ITGB3 (0.67) | ITGB3ITGA2BPPARGPPARAACE | |
| SCHEMBL3728960 | 0.96 | ITGB3 (0.64) | ITGB3ITGA2BPPARGPPARAACE | |
| SCHEMBL3728957 | 0.96 | ITGB3 (0.64) | ITGB3ITGA2BPPARGPPARAACE | |
| SCHEMBL8091309 | 0.90 | ITGB3 (0.57) | ITGB3ITGA2BPPARGPPARAACE | |
| SCHEMBL16124030 | 0.90 | ITGB3 (0.57) | ITGB3ITGA2BPPARGPPARAACE | |
| SCHEMBL16228288 | 0.90 | ITGB3 (0.57) | ITGB3ITGA2BPPARGPPARAACE | |
| SCHEMBL16228287 | 0.90 | ITGB3 (0.57) | ITGB3ITGA2BPPARGPPARAACE | |
| SCHEMBL12062761 | 0.90 | ITGB3 (0.57) | ITGB3ITGA2BPPARGPPARAACE | |
| SCHEMBL16228734 | 0.90 | ITGB3 (0.57) | ITGB3ITGA2BPPARGPPARAACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 245 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119528812-B | Double amino acid-genipin derivative and preparation method and application thereof | 广东工业大学 | 2025-06-03 | — | — | CN | claimed |
| CN-119528812-A | Double amino acid-genipin derivative and preparation method and application thereof | 广东工业大学 | 2025-02-28 | — | — | CN | claimed |
| CN-112010945-B | Preparation method of carbetocin impurity Gly9-OH | 成都诺和晟泰生物科技有限公司 | 2022-09-16 | — | — | CN | claimed |
| CN-112142825-B | Method for synthesizing carbetocin in fragment mode | 山东辰龙药业有限公司 | 2022-03-11 | — | — | CN | claimed |
| US-5767158-A | FOR BLEACHING SKIN | SHISEIDO CO., LTD. (JP) | 1998-06-16 | — | — | US | claimed |
| EP-4727552-A2 | PASSIVE PERMEABLE PCSK9 ANTAGONIST COMPOUNDS | Merck Sharp & Dohme LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PEPTIDREAM INC (JP) | 2026-01-15 | — | — | US | disclosed |
| US-20250325508-A1 | MODULATORS OF PROTEASOME DYNAMICS AND/OR FUNCTION, COMPOSITIONS, METHODS, AND THERAPEUTIC USES THEREOF | TECHNION RES & DEV FOUNDATION (IL) | 2025-10-23 | — | — | US | disclosed |
| US-20250243196-A1 | CITRON KINASE INHIBITORS | THE CLEVELAND CLINIC FOUNDATION | 2025-07-31 | — | — | US | disclosed |
| CN-119528812-B | Double amino acid-genipin derivative and preparation method and application thereof | 广东工业大学 | 2025-06-03 | — | — | CN | disclosed |
| WO-2025090774-A1 | CHEMOTHERAPEUTIC COMPOUNDS AND METHODS OF USE | SEAGEN INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| EP-4534524-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PeptiDream Inc. (JP) | 2025-04-09 | — | — | EP | disclosed |
| EP-0403828-A1 | Renin-inhibiting peptides, their preparation and their use in medicaments | BAYER AG (DE) | 1990-12-27 | — | — | EP | disclosed |
| EP-0401963-A1 | Phosphonopeptides with collagenase inhibiting activity | Beecham Group p.l.c. (GB) | 1990-12-12 | — | — | EP | disclosed |
| EP-0396065-A1 | Novel amino acid derivatives possessing renin-inhibitory activities | Japan Tobacco Inc. (JP) | 1990-11-07 | — | — | EP | disclosed |
| WO-1990002137-A1 | RENIN INHIBITORY PEPTIDES CONTAINING SULEPTANIC ACID OR DERIVATIVES THEREOF | THE UPJOHN COMPANY (US) | 1990-03-08 | — | — | WO | disclosed |
| EP-0312157-A2 | Tetrapeptide renin inhibitors having a novel c-terminal amino acid | MERCK & CO. INC. (US) | 1989-04-19 | — | — | EP | disclosed |
| EP-0071926-B1 | NEW RIBOFURANURONIC ACID DERIVATIVES, PROCESSES FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-10-08 | — | — | EP | disclosed |
| US-4508645-A | CYCLIC OLIGOPEPTIDE CONTAINING PENICILLAMINE RESIDE | CESKOSLOVENSKA AKADEMIE VED (CS) | 1985-04-02 | — | — | US | disclosed |
| US-4479942-A | Tetrahydrofurnancarboxylic acid derivatives, processes for preparation thereof and pharmaceutical compositions thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325508-A1 | MODULATORS OF PROTEASOME DYNAMICS AND/OR FUNCTION, COMPOSITIONS, METHODS, AND THERAPEUTIC USES THEREOF | PSMC1, PSME3, PSMA6 | ITGB3 3677/4885ITGA2B 3843/4885PPARG 3376/4885 |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | NSUN3, BCAT1, SLC43A1 | ITGB3 2864/4885ITGA2B 3805/4885PPARG 3131/4885 |
| US-20250243196-A1 | CITRON KINASE INHIBITORS | CHEK2, CILK1, DCK | ITGB3 3226/4885ITGA2B 3237/4885PPARG 3094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.